I am surprised that the Mammoth article could have had any effect at all. That is certainly not a significant revenue generating deal which is really what the company needs to get the pps out of the crapper. All the hype and bruhaha that we've seen over the past year have been nothing but fluff and cannot increase the pps and sustain it at a respectable level. I am afraid all we have here is a trading vehicle for those skilled in that art.
The fact that no pr has issued from all that Merck/Moffitt noise confirming DNAG as a viable partner in the M2GEN deal leads me to believe no one is seriously considering what DNAG has to offer to be a viable personalized medicine contribution for the M2GEN objectives.
News 
Market Data 
Discover 
